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Abstract 
Objective: To explore community pharmacists’ understanding and opinions in relation to prevention 
of fungal colonisation of voice prostheses amongst laryngectomy patients. 
Method: Semi-structured interviews were conducted on a purposive sample of 12 community 
pharmacists from the North of England. Interviews were undertaken until data saturation was 
reached and responses were transcribed verbatim and analysed using a thematic approach. 
Key findings: Six themes emerged from the data analysis. These were: terminology confusion about 
laryngectomy, stoma and voice prostheses; smoking as a risk factor for the development of laryngeal 
cancer; using nystatin to prevent biofilm formation; counselling information related to nystatin; 
prescription intervention and additional education in relation to laryngectomy. The theme of 
counselling information related to nystatin use and additional education was a key finding: our data 
show that when dispensing nystatin to patients with a voice prosthesis, community pharmacists 
would either give no advice related to medication use or would give incorrect advice that may lead 
to premature prosthesis failure amongst this patient group. 
Conclusion: This study highlights that community pharmacists lack understanding in relation to 
laryngectomy and are unaware of the off-label doses and administration methods of the drugs 
(specifically nystatin) used to prevent fungal colonisation on voice prostheses. Additional 
information sources – possibly obtained through the local Speech and Language Therapy 
Department – in the form of an educational leaflet would be perceived as a valuable resource to 
support community pharmacists who are required to manage these patients in the community.  
Keywords: Head and neck cancer, community pharmacists, laryngectomy, off-label prescribing, voice 
prosthesis. 
 
 
Introduction 
Head and neck cancer encompasses a range of tumours that develop in the head and neck, including 
the nasal cavity, sinuses, lips, mouth, salivary glands, throat or larynx; they are now the sixth most 
common cancer in the world, causing an estimated 350,000 deaths per year. Worldwide, tumours of 
the oral cavity and pharynx are the most common type of head and neck cancer at around 480,000 
cases per year, while cancer of the larynx results in an estimated 160,000 cases per year.[1] Similarly, 
in England, cancers of the oral cavity and pharynx are the most common forms of head and neck 
cancer, followed by cancer of the larynx – a cancer that is linked to smoking and excessive alcohol 
intake. Between 2002 and 2006 the incidence of laryngeal cancer in the North East region was an 
age-standardised rate of 4.39 per 100,000 with an age-standardised mortality of 1.36 per 
100,000.[2] During 2009/10 around 570 laryngectomies were performed in England, the majority of 
which were to treat advanced laryngeal cancer.[3] 
Locally advanced laryngeal cancer is managed by a total laryngectomy, a procedure where the entire 
larynx is removed. This procedure is relatively successful, although removal of the vocal cords poses 
the obvious problem of a patient being unable to speak after the operation. At present, a voice 
prosthesis can be inserted into the patient’s neck, which helps with voice restoration. Unfortunately, 
all voice prostheses can, over time, fail and leak, which, if left unchanged, can lead to the 
development of aspirational pneumonia – a potentially fatal complication.[4] On occasion, voice 
prostheses can fail prematurely, which not only increases the risk of developing aspirational 
pneumonia, but is also inconvenient for patients (due to frequent visits to hospital to get the 
prosthesis replaced) and expensive to the healthcare provider (one prosthesis can typically cost 
around £200 before taking into account the clinic time required to fit it). The premature ‘failing’ of 
voice prostheses has therefore been the subject of considerable investigation, leading to the 
thought that formation of a biofilm (colonisation of fungi and bacteria) on the oesophageal side of 
the prosthesis contributes to this failure.[5][6]  
Candida albicans, a naturally occurring fungal species in the body, is the most prevalent isolate 
found on voice prostheses and is considered one of the main causes of premature prosthesis 
failure.[7] As a result, patients with voice prostheses use antifungal agents to prevent biofilm 
formation and, ultimately, premature prosthesis failure. Typically, high doses of antifungal agents 
are used which constitutes ‘off-label’ use of the drug. Off-label use refers to when a licensed 
medicine is prescribed outside its marketing authorisation and should only be considered when 
there is no licensed medicine available to meet the clinical need of the patient. Community 
pharmacists play a crucial role in the supply of medicines off-label and have a responsibility to make 
prescribers aware that they are prescribing a medicine outside of its marketing authorisation.[8] 
Doctors also have a responsibility to provide patients with sufficient information about the medicine 
so an informed decision can then be made by the patient.[9] Nystatin liquid is used off-label at a 
dose of 500,000 units twice daily to prevent colonisation of Candida albicans on the voice prosthesis. 
The patient is advised to hold the nystatin in their mouth for six to eight minutes before swallowing 
and then have nothing to eat or drink for one hour afterwards. Therefore both the dose and the 
method of administration are different from the licensed particulars.[10][11] This regimen should be 
undertaken by patients on a daily basis throughout their life with a voice prosthesis to reduce the 
probability of biofilm formation (and ultimately valve failure). Unfortunately, information related to 
this ‘off-label’ use (and associated dose) is not readily available; it is not listed in the British National 
Formulary (BNF) or the Summary of Product Characteristics (SPC).[12][13]  
Patients who have undergone a total laryngectomy are, in part, managed in the community in 
partnership with speech and language therapists in secondary care. Community pharmacists are 
involved in the care pathway of these patients with responsibility for supply of laryngectomy 
appliances, such as cleaning brushes and protectors as well as the drugs used for antifungal 
prophylaxis.[14]  
Aim of the Study 
To explore community pharmacists’ understanding and opinions in relation to prevention of fungal 
colonisation of voice prostheses amongst laryngectomy patients. As the North of England has the 
highest rates of laryngeal cancer in England, it was decided to conduct the study in this region. 
Methods 
Design 
This study used qualitative methods, in the form of semi-structured interviews to examine 
community pharmacists’ understanding and opinions of issues related to the treatment of 
laryngectomy. 
Participants 
Community pharmacists who work in the North East of England were invited to take part in the 
study. 
Sample 
All community pharmacies within the geographical area with details of the study were approached in 
writing to invite them to participate in the study (n = 95). Those who responded positively were 
contacted and given further written information regarding the study.. To achieve maximum variation 
in our sample based on their time spent in practice, 20 community pharmacists were invited for 
interview.  The researcher (SK) carried out the interview at a location chosen by the community 
pharmacist. Each interview lasted approximately 30 minutes.  
Interview schedule- content and development 
The interview questions were developed after several meetings with speech and language therapists 
based at a regional hospital in the North of England. The interview questions were piloted with two 
community pharmacists and, based on feedback, were modified for the main set of interviews. The 
understanding and opinions of community pharmacists in relation to laryngectomy and fungal 
colonisation on voice prostheses are unknown, and we were interested in finding out whether there 
was any role played by time spent in practice.  
Semi-structured interviews commenced by asking the interviewee about their training and 
experience as a community pharmacist. After this, the interviewee was asked a set of open-ended 
questions and prompted when appropriate to allow further discussion and elaboration of points: 
1. What knowledge do you have concerning total laryngectomy as a surgical intervention or 
laryngectomy patients as a group? 
2. Do you know what a voice prosthesis is, and how a patient may end up with a stoma, or a 
voice prosthesis inserted within the neck? 
3. Can you explain what a stoma and voice prosthesis is in your own words? 
4. What do you think are the most significant risk factors contributing to laryngeal cancer? 
5. What drugs are used to prevent fungal growth on a voice prosthesis? 
6. If you were presented with a prescription for nystatin liquid at a dose of ‘5 mL twice daily’, 
how would you respond? 
7. What counselling or advice would you give to a patient with a voice prosthesis taking an 
antifungal to prevent fungal colonisation? 
8. Do you think extra training should be given to community pharmacists when managing 
laryngectomy patients fitted with a voice prosthesis? 
Interview conduct  
Interviews were taped and then transcribed verbatim; handwritten observational field notes were 
recorded electronically. The typed transcript was reviewed by the researcher and compared with the 
field notes made during the interview to ensure meaning had not been lost in the transcription 
process. The data were then analysed using a thematic approach consisting of the following stages: 
familiarisation with the data by re-reading of the transcripts; generating initial codes, searching for 
themes; reviewing themes, defining themes and reporting themes.[15] This process was led by the 
primary researcher (SK), but was reviewed by the first author (AT) who read transcripts, discussed 
and confirmed coding and interpretation. 
The project was certified for ethical approval by the senior researcher (AT) in accordance with the 
University of Sunderland Ethics Committee.  
Results  
Twenty community pharmacists were invited to participate and 12 (7 female) agreed to take part 
(60%).. The mean number of years qualified as a pharmacist was 16 (standard deviation 12; range 3 
– 41 years).  Data collection took place between February and May 2012 continuing until data 
saturation was reached. 
The following six themes were identified in the transcripts: terminology confusion about 
laryngectomy, stoma and voice prostheses; smoking as a risk factor for the development of laryngeal 
cancer; using nystatin to prevent biofilm formation; counselling points; prescription interventions 
and additional education. 
1. Terminology confusion about laryngectomy, stoma and voice prostheses  
Participants conceded they did not know what the terminology meant or they identified it in other 
contexts not related to voice prostheses or laryngectomy. 
A stoma is just in the lower part of the abdomen where faeces is excreted from. Pharmacist 
B, 5 years qualified. 
A stoma is part of a plant cell, isn’t it? Pharmacist G, 17 years qualified. 
One participant reported they had patients to whom they dispensed laryngectomy appliances, but 
did not specifically know what a stoma or a voice prosthesis was. 
Yes well I’ve got two patients in the community that I supply laryngectomy equipment to… 
no, I couldn’t tell you what a voice prosthesis is. Pharmacist E, 7 years qualified. 
In addition, participants also appeared to lack knowledge regarding laryngectomy as a procedure 
and as a patient group. For example, their answer for some questions, although confident, revealed 
terminology confusion – one participant thought laryngectomy was reversible. In this case, it is 
possible the participant confused a laryngectomy with a tracheostomy, which is a reversible 
procedure.  
Well, I deal with a couple of patients in my pharmacy, in regards to supplying devices I do 
have fairly good knowledge base on that front - my patients include one child with [a] 
reversible laryngectomy. Pharmacist E, 7 years qualified. 
Observational behaviours identified from the field notes suggested that some participants initially 
appeared confident when first asked about laryngectomy but, when asked further questions to 
probe knowledge, they became uncomfortable and anxious. 
2. Smoking as a risk factor for the development of laryngeal cancer  
This theme expressed the general consensus that smoking is a risk factor for the development of 
laryngeal cancer, although in the majority of cases, the participants were not confident in their 
responses and used terminology such as ‘probably’, ‘guess’ and ‘presume’.  
I’m not sure but I would guess that smoking would have a part to play in it. Pharmacist C, 8 
years qualified. 
One participant mentioned other risk factors for the development of laryngeal cancer such as 
alcohol, genetics and environmental factors. This participant was also more confident in their 
answer and used the term ‘definite’.  
Well, I think smoking is a definite cause as well as alcohol. Genetics may also play a part in it 
and chemicals so when patients may possibly breathe in toxic material from a nuclear power 
plant that contributes to cancers developing. Pharmacist A, 8 years qualified. 
3. Using antifungals to prevent biofilm formation 
All participants suggested that antifungal medication could be used to prevent fungal growth on 
voice prostheses. The participants indicated that a wide range of antifungal medication could be 
used for this purpose and included the azoles (or the imidazoles), amphotericin and nystatin. 
Participants who had experience with this patient group were more confident in their answers – 
with one giving a typical dosage used, compared to other participants with less experience. A word 
used frequently by participants when describing this association was ‘assume’ which was not 
observed as a reflection of the uncertainty in relation to the efficacy of the prophylactic use of 
antifungals in biofilm formation, but rather an expression of lack of confidence.  
They use nystatin 5 mL four times a day. One of my patients is on that and I had to ring 
Medicines Information to confirm the dose. That is what the hospital use for the prevention 
of fungal growth. Pharmacist A, 8 years qualified. 
I have not had any experience of it, I wouldn’t know. I would assume it’s the regular 
antifungal – the azoles – but honestly, I don’t know. Pharmacist H, 15 years qualified. 
Only one participant mentioned the route of drug administration when using the antifungal 
medication to prevent biofilm formation on voice prostheses. This participant differentiated 
between topical and systemic application and suggested miconazole gel could be used for topical 
application, while fluconazole could be used for systemic administration.  
If topical treatment was warranted, perhaps miconazole? Or if systemic is needed something 
like fluconazole? Pharmacist J, 3 years qualified. 
4. Prescription interventions 
All of the participants in the study group, if presented with a prescription for nystatin, at a dose of 
500,000 units twice a day, recognised that this was not the licensed dose and would consequently 
either check this with the patient or the prescriber. Only one of the participants additionally 
recognised that this was a typical dose of nystatin used for laryngectomy patients to prevent biofilm 
formation on voice prostheses. 
Well prior to having this patient I have at the minute, I would have thought what on earth is 
happening but, because I’ve got that dose, I would check if they have had a laryngectomy. 
But when I initially got that prescription, first of all, I phoned the GP. Pharmacist E, 7 years 
qualified. 
When talking about the prescription interventions, the observations in the field notes suggested that 
the participants appeared to be more confident and assertive and used terminology such as 
‘certainly’, ‘definitely’ and ‘find out exactly’.  
5. Counselling in relation to nystatin use for laryngectomy 
A theme emerged that community pharmacists would decline to offer additional advice to 
laryngectomy patients when using antifungals as biofilm prophylaxis in comparison to patients 
receiving antifungal medication for other complaints.  
I don’t think any new advice should be given. Pharmacist B, 5 years qualified. 
The majority of the participants felt that providing advice to patients was important, but patients 
were counselled according to medication type rather than according to individual-patient need or 
the indication of use. For patients receiving nystatin as antifungal prophylaxis, counselling would 
focus on ‘the standard information’, which included the importance of using the medication 
topically. Some participants referred to patients using the nystatin for several days after the lesions 
have healed suggesting that the advice is primarily aimed at patients using it for the treatment of 
oral candidiasis demonstrating an unawareness of the specialist use of nystatin. 
With that drug [nystatin] you would suggest they continue on for a period of a couple of days 
after it has cleared to make sure it has cleared. Pharmacist C, 8 years qualified. 
Two of the participants declined to offer additional advice to patients when dispensing antifungal 
medication and therefore would not offer any unless specifically asked. 
Unless specifically asked by a patient, I wouldn’t normally give any advice. Pharmacist L, 37 
years qualified. 
6. Additional education 
Some of the participants expressed a lack of confidence in dealing with laryngectomy patients and 
recognised they lacked knowledge in this area. In addition, some felt that as they were not from a 
‘hospital’ or ‘clinical’ environment, they had little experience of dealing with this patient group. One 
issue that emerged in several interviews was community pharmacists made a clear distinction 
between themselves working in community in primarily a dispensing and information giving 
capacity, in comparison to hospital pharmacists who they felt had more of a clinical role. Participants 
perceived hospital pharmacists as having greater clinical knowledge than community pharmacists 
and often used the words ‘hospital’ and ‘clinical’ interchangeably. 
I am not from a clinical or hospital environment so I haven’t had much experience really. 
Pharmacist D, 16 years qualified. 
The participants felt that encountering patients with laryngectomy in the community was relatively 
‘rare’, additional training for treatment of laryngectomy prostheses would not be valuable or even 
warranted. In addition, several of the participants also perceived patients with voice prostheses as 
‘experts’ and valuable sources of information in relation to laryngectomy. However, despite this, all 
participants wanted a ‘quick’ information source they could refer to regarding laryngectomy patients 
and the drugs used to prevent fungal colonisation on voice prostheses.  
I’ve been working in practice for over a decade and never had it affect me as a pharmacist. I 
think, however, something you can quickly refer to should be available but should everyone 
be subjected to training? No. Reading something – a leaflet – is always a good source to 
have. Pharmacist H, 15 years qualified. 
Discussion 
Summary of the main findings 
In summary, this study found several issues emerged from interviews with community pharmacists 
regarding laryngectomy. These issues included confusion about terminology related to 
laryngectomy, stoma and voice prostheses; inconsistency or uncertainty around the use of nystatin 
to prevent biofilm formation; provision of standard counselling for nystatin use, rather than tailored 
for voice prostheses; and a desire for additional information on off-label doses and administration 
methods of the drugs used to prevent fungal colonisation on voice prostheses. 
Strengths and Limitations 
This is one of the first studies to examine community pharmacists’ understanding opinions of issues 
related to the treatment of laryngectomy. Community pharmacists have an important role in the 
management of laryngectomy and voice prostheses; this study has helped to clarify issues in relation 
to this support. Although voice prostheses for laryngectomy are not common, the results of this 
study may provide suggestions for the needs of community pharmacists in relation to the care of 
patients having other uncommon conditions. We believe our results are robust and have important 
implications for the treatment of laryngectomy patients with voice prostheses by community 
pharmacists, and perhaps more widely in relation to community pharmacists delivering specialist 
clinical services. However, only community pharmacists from the North of England were surveyed. In 
addition, the interpretation of the observed mannerisms of the participants was entirely that of the 
researcher [SK] and not independently checked. Generalisation of this work to all community 
pharmacists in England and more widely should therefore be made carefully.  
Relation to prior work and implications for policy and practice  
A key finding was that when dispensing antifungal medication to patients with a voice prosthesis, 
some of the community pharmacists would not give any advice regarding the use of the medication. 
These pharmacists had been registered for the longest period of time amongst all of the participants 
in the study. Indeed, one of the key standards of performance as outlined by the pharmacy regulator 
in the UK, the General Pharmaceutical Council (GPhC), is to ‘be satisfied that patients or their carers 
know how to use their medicines’.[16] Clearly, to meet these standards communicating with and 
counselling patients about their medicine(s) is essential, particularly when a medicine has been 
prescribed off-label. There is no differentiation within this as to how rarely one may encounter a 
particular situation in practice and thus all patients should expect to receive the same standard of 
care.  
A possible reason for the observation of differences in the counselling provided by pharmacists 
could be that the role of the community pharmacist has changed, with the emphasis taken from 
solely dispensing medication to a more patient-focused role.[17] In addition to the requirements of 
the GPhC, and as part of the Pharmacy Contractual Framework in England, all community 
pharmacists are required to dispense medication and provide information and advice to ensure safe 
and effective medicines use by patients and carers.[18] In view of this change in role, the training of 
pharmacists has also evolved, with pharmacy degrees typically having more focus on clinical content 
and pharmaceutical care than was previously the case. It is plausible that training given to more 
recently qualified pharmacists has prepared them with the skills to effectively counsel patients about 
their medicines, while pharmacists who have been registered longer may not have had specific 
training on the importance of effective counselling in terms of appropriate medicines use. While 
previous work has found that community pharmacists are aware of the issues that surround off-label 
prescribing, this knowledge appears to be gained through experience rather than undergraduate or 
postgraduate training.[19] In our study, community pharmacists who have been registered the 
longest amongst our sample were less likely to offer additional advice when supplying laryngectomy 
patients antifungals, although it is not clear if they recognised that this was an off-label use of the 
medication. This observation may prove to support a training opportunity for community 
pharmacists, but is clearly based upon our limited sample and should not be generalised without 
further investigation.  
In general, community pharmacists would not give additional advice to patients with a voice 
prosthesis when using antifungals as prophylaxis against Candida growth beyond that given to other 
patients using it for the treatment of oropharyngeal candidiasis. This group included pharmacists 
who already dispense medication to patients with voice prostheses. These findings are of significant 
value as patients fitted with a voice prosthesis are advised to use nystatin twice a day for five to 
eight minutes following the ‘swish-and-swallow’ protocol.[11] This method of administration is 
different when compared to using it for the regular treatment of oropharyngeal candidiasis and, as 
such, counselling for patients (and training for staff) should reflect this difference. If the technique of 
administration is not periodically reinforced by community pharmacists at the time of dispensing, 
patients may become non-adherent, increasing the risk of prosthesis failure and, more significantly, 
aspirational pneumonia. In addition, for patients taking high dose nystatin as fungal prophylaxis, it 
would be appropriate to offer advice about oral hygiene (such as cleaning teeth/dentures before 
bed). Nystatin contains sugar, which can have implications for this patient group, as teeth can often 
be damaged as a result of radiotherapy. If patients are using nystatin immediately prior to retiring to 
bed without taking the appropriate actions in relation to oral hygiene, there is potential for further 
damage of the teeth. 
 Community pharmacists interviewed suggested one way to improve understanding of this patient 
group could be to supply information in the form of a leaflet sent directly from the Speech and 
Language Therapy Department, when a patient uses it to obtain their laryngectomy equipment and 
antifungal medication. The leaflet could contain background information to laryngectomy, give 
general advice about voice prostheses (such as cleaning regimens) and provide information related 
to the off-label use of antifungals in this patient group.  
These findings have not been reported elsewhere in the literature, although it has been 
acknowledged that hospital pharmacists have an important role in optimising treatment for patients 
with head and neck cancer, suggesting that such pharmacists may indeed have better knowledge of 
this patient group.[20] Hospital pharmacists, in contrast to community pharmacists, however, work 
as part of the wider healthcare team. Working predominantly independently, community 
pharmacists do not have access to as many resources as those in hospitals, such as speech and 
language therapy departments for advice and training in relation to this patient group. Interestingly, 
in our study, pharmacists working in a hospital environment were perceived as being more ‘clinical’ 
by the community pharmacists and were therefore expected to have more knowledge of 
laryngectomy and the drugs used in antifungal prophylaxis. This observation is timely as a recent 
study regarding pharmacists’ perceptions of their role and professional identity showed that the role 
of a clinical practitioner was more prevalent in hospital pharmacists than community 
pharmacists.[21] In the same study, community pharmacists, despite spending time communicating 
with patients about medicines use, never described their work as ‘clinical’. Indeed, as proposals have 
been made to transfer specialist clinical services from secondary to primary care (e.g. community 
pharmacists dispensing oral chemotherapy in primary care [22]), our observation warrants further 
investigation as it may prove to be a barrier for community pharmacists delivering specialist clinical 
services.  
Conclusion 
In summary, this study highlights that community pharmacists lack understanding in relation to 
laryngectomy and are unaware of the off-label doses and administration methods of the drugs 
(specifically nystatin) used to prevent fungal colonisation on voice prostheses. Additional 
information sources – possibly obtained through the local Speech and Language Therapy 
Department – in the form of an educational leaflet would be perceived as a valuable resource to 
support community pharmacists who are required to manage these patients in the community.  
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